Matrix metalloproteinases (MMPs) play a critical role in angiogenesis, the process of forming new blood vessels from existing ones. This process is essential for wound healing, rheumatoid arthritis, and tumor growth and metastasis. MMPs are a family of extracellular enzymes that degrade components of the extracellular matrix (ECM), enabling endothelial cell migration, proliferation, and the formation of new blood vessels. The most studied MMPs in angiogenesis are MMP-2 and MT-1-MMP, which are involved in ECM degradation and the formation of vascular sprouts. MMP activity is regulated by tissue inhibitors of metalloproteinases (TIMPs), which can inhibit MMP function and thus modulate angiogenesis. MMPs are involved in various stages of angiogenesis, including the degradation of the ECM to allow endothelial cell migration, the formation of new capillaries, and the regulation of endothelial cell behavior. The activation of MMPs is often dependent on interactions with integrins, such as αvβ3, which can influence MMP activity and localization on the cell surface. The PEX domain of MMPs is involved in binding to integrins and can compete with MMP-2 for binding to αvβ3, potentially inhibiting MMP-2 activity. Recent studies have shown that MMPs can also generate angiogenesis inhibitors, such as angiostatin, which can inhibit tumor growth. MMP-12 is particularly potent in generating angiostatin, which inhibits microvascular endothelial cell proliferation. Additionally, MMPs may contribute to the generation of endostatin, a proteolytic fragment of collagen XVIII that inhibits angiogenesis. Understanding the specific roles of MMPs in angiogenesis is crucial for developing targeted therapies for diseases such as cancer. Current therapeutic approaches using MMP inhibitors have resulted in side effects, highlighting the need for more specific inhibitors. Research into the molecular mechanisms of MMP activity and its regulation by TIMPs and integrins is essential for developing effective and safe therapeutic strategies. The dynamic nature of MMP activity in different ECM environments underscores the complexity of angiogenesis and the need for a deeper understanding of MMP functions to improve therapeutic interventions.Matrix metalloproteinases (MMPs) play a critical role in angiogenesis, the process of forming new blood vessels from existing ones. This process is essential for wound healing, rheumatoid arthritis, and tumor growth and metastasis. MMPs are a family of extracellular enzymes that degrade components of the extracellular matrix (ECM), enabling endothelial cell migration, proliferation, and the formation of new blood vessels. The most studied MMPs in angiogenesis are MMP-2 and MT-1-MMP, which are involved in ECM degradation and the formation of vascular sprouts. MMP activity is regulated by tissue inhibitors of metalloproteinases (TIMPs), which can inhibit MMP function and thus modulate angiogenesis. MMPs are involved in various stages of angiogenesis, including the degradation of the ECM to allow endothelial cell migration, the formation of new capillaries, and the regulation of endothelial cell behavior. The activation of MMPs is often dependent on interactions with integrins, such as αvβ3, which can influence MMP activity and localization on the cell surface. The PEX domain of MMPs is involved in binding to integrins and can compete with MMP-2 for binding to αvβ3, potentially inhibiting MMP-2 activity. Recent studies have shown that MMPs can also generate angiogenesis inhibitors, such as angiostatin, which can inhibit tumor growth. MMP-12 is particularly potent in generating angiostatin, which inhibits microvascular endothelial cell proliferation. Additionally, MMPs may contribute to the generation of endostatin, a proteolytic fragment of collagen XVIII that inhibits angiogenesis. Understanding the specific roles of MMPs in angiogenesis is crucial for developing targeted therapies for diseases such as cancer. Current therapeutic approaches using MMP inhibitors have resulted in side effects, highlighting the need for more specific inhibitors. Research into the molecular mechanisms of MMP activity and its regulation by TIMPs and integrins is essential for developing effective and safe therapeutic strategies. The dynamic nature of MMP activity in different ECM environments underscores the complexity of angiogenesis and the need for a deeper understanding of MMP functions to improve therapeutic interventions.